This did not reach statistical significance overall due to a small sample size, however significance was noted in both studies in an exploratory analysis of the sub-group of patients with tumours expressing low levels of PD-L1 suggesting a potential benefit in “cold” tumours.
← all excerpts
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
1
—
—